Related Experiment Video
Updated: Jun 4, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
Pharmacology of antisense therapeutic agents : cancer and inflamination
C F Bennett1, N Dean, D J Ecker
1ISIS Pharmaceuticals, Carlsbad, CA.
Abstract:
Antisense oligonucleotides represent a new paradigm for drug discovery that holds great promise to deliver potent and specific drugs with fewer undesired side effects. The antisense paradigm offers the opportunity to identify rapidly lead compounds based on knowledge of the biology of a disease process, and a relevant target gene sequence. With this information, the practitioner of antisense drug discovery can rapidly design, synthesize, and test a series of compounds in cell culture and determine if the target gene is specifically inhibited. A compound thus identified can then be tested in an animal model, either to determine whether targeted gene expression can be inhibited in various animal tissues or to determine if there is activity in an animal model of a human disease. The length of time and the resources required to identify a lead compound by the antisense paradigm is much less than by any other drug discovery method.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inhibitors of Viral Protein Synthesis
Experimental RNAi
Pharmacogenomics: Identification of New Drug Targets
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
